Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
NCT06572839 · View on ClinicalTrials.gov ↗
Study Summary
This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers
Conditions Studied
Interventions
- OTHER Amnio-Maxx
Study Locations (12)
Florida
- Solutions Medical Research — Coral Gables
- Evolution Research Center — Hialeah
- Symphony Research — Jacksonville
- Quality Care Clinical Research — Miami
Texas
- Stride Clinical Research — Houston
- Ten20 Medical — Sunnyvale
Alabama
- North Alabama Research Center, LLC — Athens
California
- North Park Podiatry — San Diego
Louisiana
- Medcentris — Hammond
New Jersey
- Curalta Clinical Trials — Oradell
New York
- Suffolk Foot and Ankle — East Patchogue
Pennsylvania
- PA Foot and Ankle Associates — Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-10-25 |
| Est. Completion | 2025-10-31 |
| Phase | NA |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06572839
The ClinicalTrials.gov registry entry for NCT06572839 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Capsicure, which has 3 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Diabetic Foot Ulcer appearing as the primary indexed condition, and to 1 intervention — of which Amnio-Maxx is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT06572839 reports 12 study locations spanning 8 distinct geographic areas — top geographies include Florida, Texas, Alabama. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT06572839 about?
NCT06572839 is a clinical study titled "Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone". This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers
What is the current status of trial NCT06572839?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-10-25. Estimated completion is 2025-10-31.
What conditions does trial NCT06572839 study?
This clinical trial studies the following conditions: Diabetic Foot Ulcer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT06572839?
The interventions under investigation include: Amnio-Maxx (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT06572839?
This trial is sponsored by Capsicure, which has 3 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT06572839 being conducted?
This trial has 12 study locations across Alabama, California, Florida, Louisiana, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.